HJC0152

News alerts, weekly reports and conference planners

Company:

The University of Texas, Tianjin Medical University Cancer Institute and Hospital, UT MD Anderson Cancer Center

Drug class:

STAT3 inhibitor, Glucose metabolism modulator

Related drugs:

over5years

HJC0152 suppresses human non-small-cell lung cancer by inhibiting STAT3 and modulating metabolism. (PubMed, Cell Prolif)

HJC0152 reduces cellular capacity to scavenge free radicals, leading to ROS generation and accumulation and apoptosis. This study provides a rationale for further developing HJC0152 as a potential therapy for NSCLC and provides insights into the mechanisms by which HJC0152 exerts its anti-cancer effects.

over 5 years ago

Journal

STAT3 (Signal Transducer And Activator Of Transcription 3)

HJC0152